| ADR Ontology |
| ADR Term |
Hyperparathyroidism |
| ADR ID |
BADD_A02134 |
| ADR Hierarchy |
|
| Description |
A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood). [CTCAE] A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. [MeSH] |
| MedDRA Code |
10020705 |
| MeSH ID |
D006961
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
|
| Synonym |
| Hyperparathyroidism | Hyperparathyroidism NOS |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Parathyroid hormone/parathyroid hormone-related peptide receptor | Q03431 | T67710 |
|
| Drugs Leading to the ADR |
|
|
